302 related articles for article (PubMed ID: 22894958)
41. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees.
Velumani S; Toh YX; Balasingam S; Archuleta S; Leo YS; Gan VC; Thein TL; Wilder-Smith A; Fink K
Hum Vaccin Immunother; 2016 May; 12(5):1265-73. PubMed ID: 26889737
[TBL] [Abstract][Full Text] [Related]
42. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
43. Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4-5 Years After a Primary 3-Dose Schedule.
Coronel D; García-Rivera EJ; Rivera M; Arredondo-García JL; Dietze R; Perroud AP; Cortés M; Bonaparte M; Zhao J; Tila M; Jackson N; Zambrano B; Noriega F
Pediatr Infect Dis J; 2019 May; 38(5):e90-e95. PubMed ID: 30986790
[TBL] [Abstract][Full Text] [Related]
44. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
[TBL] [Abstract][Full Text] [Related]
45. Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey.
Ravel G; Mantel N; Silvano J; Rogue A; Guy B; Jackson N; Burdin N
Vaccine; 2017 Oct; 35(43):5918-5923. PubMed ID: 28882438
[TBL] [Abstract][Full Text] [Related]
46. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
[TBL] [Abstract][Full Text] [Related]
47. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials.
da Costa VG; Marques-Silva AC; Floriano VG; Moreli ML
Vaccine; 2014 Sep; 32(39):4885-92. PubMed ID: 25045816
[TBL] [Abstract][Full Text] [Related]
48. The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.
Glass A; Polhemus M; Wang D; Jarman RG; Thomas SJ; Friberg H; Currier JR; Bonaparte M; De La Barra R; Princiotta MF; Abbott M; Cuzzo B; Machabert T; Sridhar S; Endy TP
J Infect Dis; 2020 Mar; 221(7):1057-1069. PubMed ID: 31755526
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
50. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
Guy B; Briand O; Lang J; Saville M; Jackson N
Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
[TBL] [Abstract][Full Text] [Related]
51. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.
Lecouturier V; Berry C; Saulnier A; Naville S; Manin C; Girerd-Chambaz Y; Crowe JE; Jackson N; Guy B
Vaccine; 2019 Jul; 37(32):4601-4609. PubMed ID: 29706291
[TBL] [Abstract][Full Text] [Related]
52. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
[TBL] [Abstract][Full Text] [Related]
53. Dengue vaccination during pregnancy - An overview of clinical trials data.
Skipetrova A; Wartel TA; Gailhardou S
Vaccine; 2018 May; 36(23):3345-3350. PubMed ID: 29716774
[TBL] [Abstract][Full Text] [Related]
54. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
[TBL] [Abstract][Full Text] [Related]
55. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
[TBL] [Abstract][Full Text] [Related]
56. Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis.
Malisheni M; Khaiboullina SF; Rizvanov AA; Takah N; Murewanhema G; Bates M
Front Immunol; 2017; 8():863. PubMed ID: 28824613
[TBL] [Abstract][Full Text] [Related]
57. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine.
Wilder-Smith A; Massad E
Expert Rev Vaccines; 2016; 15(4):437-41. PubMed ID: 26775653
[TBL] [Abstract][Full Text] [Related]
58. CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety.
Godói IP; Lemos LL; de Araújo VE; Bonoto BC; Godman B; Guerra Júnior AA
J Comp Eff Res; 2017 Mar; 6(2):165-180. PubMed ID: 28084784
[TBL] [Abstract][Full Text] [Related]
59. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
[TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
